These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of RAS: proven and potential vulnerabilities. Zuberi M; Khan I; O'Bryan JP Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838 [TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to KRAS Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136 [TBL] [Abstract][Full Text] [Related]
4. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319 [TBL] [Abstract][Full Text] [Related]
10. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib? Oya Y; Imaizumi K; Mitsudomi T Lung Cancer; 2024 Aug; 194():107886. PubMed ID: 39047616 [TBL] [Abstract][Full Text] [Related]
11. KRAS G12C fragment screening renders new binding pockets. Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391 [TBL] [Abstract][Full Text] [Related]
12. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic. McCormick F Cancer Cell; 2020 Jan; 37(1):3-4. PubMed ID: 31951561 [TBL] [Abstract][Full Text] [Related]
14. Nonclinical Safety Profile of Sotorasib, a KRAS Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282 [TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy. Kirschner T; Müller MP; Rauh D J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359 [TBL] [Abstract][Full Text] [Related]
16. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824 [TBL] [Abstract][Full Text] [Related]
17. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701 [TBL] [Abstract][Full Text] [Related]
18. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410 [TBL] [Abstract][Full Text] [Related]
19. Targeting Son of Sevenless 1: The pacemaker of KRAS. Kessler D; Gerlach D; Kraut N; McConnell DB Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766 [TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the GTPase KRAS Xu Q; Zhang G; Liu Q; Li S; Zhang Y Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]